Is Lantern Pharma Inc (LTRN) a Stock to Watch After Losing -2.60% This Week?

Overall market sentiment has been down on Lantern Pharma Inc (LTRN) stock lately. LTRN receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Lantern Pharma Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on LTRN!

See Full LTRN Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With LTRN Stock Today?

Lantern Pharma Inc (LTRN) stock is trading at $3.74 as of 10:00 AM on Wednesday, Sep 27, an increase of $0.13, or 3.6% from the previous closing price of $3.61. The stock has traded between $3.74 and $3.75 so far today. Volume today is low. So far 1,923 shares have traded compared to average volume of 27,192 shares. To see InvestorsObserver's Sentiment Score for Lantern Pharma Inc click here.

More About Lantern Pharma Inc

Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline of development programs involves four drug candidates and an Antibody Drug Conjugate (ADC) program directed towards eight therapeutic targets. Its A.I. platform, known as RADR, includes more than 18 billion data points, and uses big data analytics and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. Click Here to get the full Stock Report for Lantern Pharma Inc stock.